bioRxivEvolutionary BiologyPreprint
High-quality SNPs from genic regions highlight introgression patterns among European white oaks (Quercus petraea and Q. robur).
T. Lang, P. Abadie, V. Leger, T. Decourcelle, J.-M. Frigerio, C. Burban, C. Bodenes, E. Guichoux, G. Le Provost, C. Robin, N. Tani, P. Leger, C. Lepoittevin, V. A. El Mujtar, F. Hubert, J. Tibbits, J. Paiva, A. Franc, F. Raspail, S. Mariette, M.-P. Reviron, C. Plomion, A. Kremer, M.-L. Desprez-Loustau, P. Garnier-Gere
Abstract
The Src homology-2 domain containing phosphatase SHP2 is a critical regulator of signal transduction, being implicated in cell growth and differentiation. Activating mutations cause developmental disorders and act as oncogenic drivers in hematologic cancers. SHP2 is activated by phosphopeptide binding to the N-SH2 domain, triggering the release of N-SH2 from the catalytic PTP domain. Based on early crystallographic data, it has been widely accepted that opening of the binding cleft of N-SH2 serves as the key "allosteric switch" driving SHP2 activation. To test the putative coupling between binding cleft opening and SHP2 activation as assumed by the "allosteric switch" model, we critically reviewed structural data of SHP2 and we used extensive molecular dynamics (MD) simulation and free energy calculations of isolated N-SH2 in solution, SHP2 in solution, and SHP2 in a crystal environment. Our results demonstrate that the binding cleft in N-SH2 is constitutively flexible and open in solution, and that a closed cleft found in certain structures is a consequence of crystal contacts. The degree of opening of the binding cleft has only a negligible effect on the free energy of SHP2 activation. Instead, SHP2 activation is greatly favored by the opening of the central {beta}- sheet of N-SH2. We conclude that opening of the N-SH2 binding cleft is not the key allosteric switch triggering SHP2 activation. Significance StatementSHP2 is a multi-domain protein, playing an important role in up-regulating cellular processes such as cell survival, proliferation, and programmed cell death. SHP2 mutations cause developmental disorders and were found in many cancer types, including neuroblastoma, breast cancer, and leukemia. In healthy cells, SHP2 mainly takes an autoinhibited, inactive form, and SHP2 is activated upon binding of phosphopeptides to the N-SH2 domain. For the past two decades, the widening of the binding cleft upon peptide binding has been considered as the key event driving SHP2 activation. Here, by analyzing crystallographic data and molecular simulations, we demonstrate that the binding cleft in N-SH2 is, instead, already open and accessible in solution, and its degree of opening does not influence SHP2 activation.
- assay: protein structure
- research focus: protein folding & dynamics
- approach: mechanistic / dynamical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation
M. Anselmi, J. S. Hub·bioRxiv·Nov 18, 2020
- An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase
M. Anselmi, J. S. Hub·Scientific ReportsPeer-reviewed·Oct 28, 2020
- Atomistic ensemble of active SHP2 phosphatase
M. Anselmi, J. S. Hub·bioRxiv·May 4, 2023
- Phosphatase SHP2 pathogenic mutations enhance activity by altering conformational sampling
Andrew Glaser, R.A.P. Padua, … Dorothee Kern·Proceedings of the National Academy of SciencesPeer-reviewed·Jan 13, 2026
- Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase
M. Anselmi, P. Calligari, … L. Stella·bioRxiv·Mar 27, 2020
- Mechanism of SHP2 activation by bis-Tyr-phosphorylated Gab1
Lisa Machner, Alaa Shaikhqasem, … Milton T. Stubbs·StructurePeer-reviewed·Dec 22, 2025